 Artelo Biosciences, Inc. ARTL, a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has expanded its existing research and worldwide commercial license agreement with The Research Foundation For The State University of New York, Stony Brook. Artelo has obtained exclusive rights to recently developed, third-generation fatty acid binding protein 5 FABP5 inhibitors. The company plans to select a lead cancer therapeutic compound from these compounds, as well as to identify additional candidates for pain, inflammation and other conditions, facilitating a potentially significant expansion to the companys development pipeline. 